नवीनतम

  • UNISOC launched 5G End-to-End Network Slicing Selection Solution with China Unicom

    UNISOC and China Unicom have successfully launched world's first 3GPP-compliant end-to-end network slicing selection solution (Note 1). It enables device to independently and flexibly select network slices through application descriptors, Domain descriptors, IP descriptors, DNN, and other business identifiers in China Unicom 5G SA's trial commercial network and bringing full-strategy slicing exper
  • 11 मिलियन अमरीकी डालर का निवेश प्राप्त करने के बाद 150

    फिन्सी को GBCI से USD 11 मिलियन का निवेश मिलने के बाद, फिन्सी सिंगापुर की टीम अपनी नवीनतम भर्ती योजना शुरू करेगी। फिन्सी को उम्मीद है कि वह दुनिया भर में 150 "रणनीतिक" प्रतिभाओं की भर्ती करेगा ताकि अपनी वैश्विक प्रतिभा टीम के निर्देशन और व्यवसाय विकास क्षमता को मजबूत किया जा सके, उपयोगकर्ता अनुभव को और अधिक अनुकूलित किया जा सके, और फिन्सी के बाजार की मांग को पूरा किया जा सके।
  • Fincy फंडिंग में GBCI US$11 मिलियन प्राप्त करता हैं

    इंटरनेशनल मेनस्ट्रीम मीडिया, “बिजनेस टाइम्स”, “एंटरप्रेन्योर्स” और अन्य रिपोर्टों के अनुसार, सिंगापुर की फाइनेंसियल टेक्नोलॉजी स्टार्ट-अप Fincy को हाल ही में प्राप्त हुई अपनी मूल कंपनी GBCI से रजिस्टर्ड कैपिटल में $11 मिलियन प्राप्त हुए हैं, जो दक्षिण पूर्व एशिया में Fincy टेक्नोलॉजी सर्विसेज और मार्केट डेवलपमेंट के लिए उपयोग किया जाएगा। कंपनी ने आगे कहा कि कैपिटल इंजेक्शन के अलावा, Fincy अगले कुछ
  • Yutong Holds Online Live-Show to Decode 5G-Enabled Intelligent Mobility for Global Viewers

    On September 8 2020, Yutong officially unveiled its 5G-enabled intelligent mobility solution at its namesake launching ceremony. One day later, at 6pm on September 9, Yutong brought intelligent technologies in a live-show on SNS. Yutong showcased its 5G-enabled intelligent mobility solution and unveiled a series of intelligent IoT technologies on Facebook, Twitter, YouTube, and Yutong’s internatio
  • A survivor of the global economic turmoil-- The rise of the"Whatsapp investment" model

    As the economic landscape becomes increasingly complex in 2020, turbulence continues to dominate the global economy. Under the Federal Reserve's guidance, three interest rate cuts by central banks in 2019 have resulted in a negative interest rate trend. Instability in the Eurozone and emerging markets has also led to weakness across many sectors of the economy.
  • A new way to play with Whatsapp -- access your investment anytime and anywhere

    Since March, Amna, an office worker from Mumbai, has learned a brand-new way to use Whatsapp.
  • If you like sports watches, you'll love this gorgeous Davis Elvin

    The Y-generation prefers trendy and cool watches, better with technological materials to demonstrate their unique personality end taste. Light in weight, unique in texture, carbon fiber is definitely a hot star in recent years. Carbon fiber has caught my eyes on an exhibition, suitable for young watch fans who like fashion and sports style.
  • Don't forget the tragic history of "Buddhist Revival Movement"

    ​Recently, it was learned through news that the Bihar government agreed that the “Central Tibetan Administration” to build the “Dalai Lama Nalanda Buddhist Research Center" in Bodh Gaya.This move by the Bihar government is contrary to the spirit and will of India's "Buddhist Revival Movement", which disappointed the whole Indian Buddhists.
  • समलैंगिकता को अपराध नहीं करार देने का फैसला बेहद खास : कांग्रेस

    कांग्रेस ने गुरुवार को सर्वोच्च न्यायालय के समलैंगिकता को अपराध नहीं करार देने के फैसले को ‘बेहद महत्वपूर्ण’ बताया और कहा कि यह एक उदार और सहिष्णु समाज की ओर एक महत्वपूर्ण कदम है। कांग्रेस नेता रणदीप सिंह सुरजेवाला ने एक ट्वीट में कहा, “सर्वोच्च न्यायालय का धारा 377 पर फैसला बेहद महत्वपूर्ण है। एक पुराना औपनिवेशिक कानून जो आज के आधुनिक समय की सच्चाई से अलग था, समाप्त हो गया, मौलिक अधिकार बहाल हुए
  • ​AET REMOULD Launches the Latest Rolex Daytona Modified Watch

    Picasso, one of the greatest artistic geniuses of the 20th century, the name has become a brilliant artistic symbol. His amazing talent and creativity exert a profound impact on the endless exploration spirit of art forms.

अनुकूल लिंक

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

05-22    

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


डिस्क्लेमर: यह लेख अन्य मीडिया से पुन: पेश किया गया है। रिप्रिंट करने का उद्देश्य अधिक जानकारी देना है। इसका मतलब यह नहीं है कि यह वेबसाइट अपने विचारों से सहमत है और इसकी प्रामाणिकता के लिए जिम्मेदार है, और कोई कानूनी जिम्मेदारी वहन नहीं करती है। इस साइट पर सभी संसाधन इंटरनेट पर एकत्र किए गए हैं। साझा करने का उद्देश्य केवल सभी के सीखने और संदर्भ के लिए है। यदि कॉपीराइट या बौद्धिक संपदा उल्लंघन है, तो कृपया हमें एक संदेश छोड़ दें।
शीर्ष पर वापस जाएँ
© Copyright 2006-2020 halloindianews.in      हमसे संपर्क करें   SiteMap